Subscribe to our Newsletters !!
Climate change is very disruptive to the Amazon ra
By 2024, there are certain things you need to do i
Insects that are given more attention and reverenc
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Delivering Clinically Documented Immune, Mood and Vaginal Benefits for Women During Pregnancy.rn
WILMINGTON, Del., June 20, 2019 – DuPont Nutrition & Biosciences has announced the launch of HOWARU® Protect Prenatal+, an innovative probiotic formula that has been clinically proven to deliver mood, vaginal and immune health benefits for women during pregnancy and beyond.
DuPont Nutrition & Biosciences is a world leader in microbial biotechnology, health, and nutrition with the broadest range of clinically documented probiotics available in the marketplace. They offer a full range of innovative science-based solutions for improved health and wellness under the brand name HOWARU®, which now features the new HOWARU® Protect Prenatal+.
State-of-the-art clinical studies with probiotic supplementation in pregnant women have provided new insights into the health of both mothers and their infants. Among the significant trials has been the ‘Probiotics in Pregnancy Study’ whose primary aim was to assess whether probiotic supplementation in women with Lactobacillus rhamnosus HN001™ provided immune benefits for infants. The secondary aims focused on the health of the mothers and the effect HN001™ supplementation had on the risk of gestational diabetes mellitus (GDM) and postnatal depression. In this “gold-standard” clinical trial of over 400 pregnant women, daily consumption of L. rhamnosus HN001™ by the mother was found to have been associated with a lower prevalence of GDM as well as lower incidence of postnatal depression and anxiety.
Additional clinical trials showed that daily consumption of L. rhamnosus HN001™ by the mother and her infant also helped infants develop a balanced immune system function in the first two years and continued to impact immune health through 11 years.
The prevalence of eczema of the children through age 11, the latest time of evaluation, was significantly reduced in the probiotic groups compared to the placebo group. In addition, at ages 6 and 11, there were significant reductions in allergic sensitization scores.
The results also showed mothers who had received the HN001™ supplement had improved levels of immune markers in cord blood and breast milk than those in the placebo group, demonstrating immune support for expectant mothers as well.
Barthow C et al., (2016) BMC Pregnancy Childbirth 16,133
Wickens KL et al., (2008) J Allergy Clin Immuno 122:788-794
Wickens KL et al., (2012) Clin Exp Allergy 42:1071-1079
Wickens KL et al., (2013) Clin Exp Allergy 43(9):1048-1057
Wickens KL et al. (2018) Pediatr Allergy Immunol. 29:808–814.
Prescott et al., 2008 Clin Exp Allergy; 39(5):771.
HOWARU&re
